It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s disease (PD) is the most common neurodegenerative motor disorder, and its pathologic hallmarks include extensive dopaminergic neuronal degeneration in the Substantia nigra associated with Lewy bodies, predominantly consisting of phosphorylated and truncated α-Synuclein (α-Syn). Asparagine endopeptidase (AEP) cleaves human α-Syn at N103 residue and promotes its aggregation, contributing to PD pathogenesis. However, how AEP mediates Lewy body pathologies during aging and elicits PD onset remains incompletely understood. Knockout of AEP or C/EBPβ from α-SNCA mice, and their chronic rotenone exposure models were used, and the mechanism of α-Syn from the gut that spread to the brain was observed. Here we report that C/EBPβ/AEP pathway, aggravated by oxidative stress, is age-dependently activated and cleaves α-Syn N103 and regulates Lewy body-like pathologies spreading from the gut into the brain in human α-SNCA transgenic mice. Deletion of C/EBPβ or AEP substantially diminished the oxidative stress, neuro-inflammation, and PD pathologies, attenuating motor dysfunctions in aged α-SNCA mice. Noticeably, PD pathologies initiate in the gut and progressively spread into the brain. Chronic gastric exposure to a low dose of rotenone initiates Lewy body-like pathologies in the gut that propagate into the brain in a C/EBPβ/AEP-dependent manner. Hence, our studies demonstrate that C/EBPβ/AEP pathway is critical for mediating Lewy body pathology progression in PD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Shanghai Jiaotong University School of Medicine, Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293); Brain Aging and Cognitive Neuroscience Laboratory of Hebei Province, Neuromedical Technology Innovation Center of Hebei Province, Department of Neurology, The First Hospital of Hebei Medical University (Department of Neurology, Hebei Hospital of Xuanwu Hospital Capital Medical University), Shijiazhuang, P. R. China (GRID:grid.452458.a); Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
2 Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Renmin Hospital of Wuhan University, Department of Neurology, Wuhan, China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270)
3 Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Hallym University, Department of Physiology, College of Medicine, Hallymdaehak-gil, Chuncheon-si, Gangwon-Do, 24252, South Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)
4 Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
5 The Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, CAS Key Laboratory of Brain Connectome and Manipulation, Shenzhen, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922); Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, 518000, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922)
6 Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Department of Mental Health and Public Health, Shenzhen, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922)
7 Shanghai Jiaotong University School of Medicine, Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
8 Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Department of Biology, Shenzhen, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922)